Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

Cancer Gene Therapy

Volumn 19, Issue 12, 2012, Pages 811-817

  Doukas, J ^a   Rolland, A ^a  

^a VICAL INC   (United States)

Author keywords

immunotherapy; lipid; melanoma; MHC class I; plasmid; T cell

Indexed keywords

B7 ANTIGEN; BETA 2 MICROGLOBULIN; CD28 ANTIGEN; CD86 ANTIGEN; HLA B ANTIGEN; HLA B7 ANTIGEN; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VELIMOGENE ALIPLASMID;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG DISTRIBUTION; DRUG MECHANISM; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR IMMUNITY;

ANIMALS; DNA, RECOMBINANT; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIPIDS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84869206956     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.69     Document Type: Review

References (58)

1. Cancer Facts and Figures 2012. American Cancer Society: Atlanta, 2012.
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Soares HP, Lutzky J. Velimogene aliplasmid. Expert Opin Biol Ther 2010; 10: 841-851.
5. Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy 2011; 3: 17-21.
6. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010; 20: 218-226.
7. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645-4649. (Pubitemid 23148962)
8. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011; 39: D913-D919.
9. Peaper DR, Cresswell P. Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol 2008; 24: 343-368.
10. Williams DB, Barber BH, Flavell RA, Allen H. Role of beta 2-microglobulin in the intracellular transport and surface expression of murine class I histocompatibility molecules. J Immunol 1989; 142: 2796-2806. (Pubitemid 19114898)
11. Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 1989; 86: 6719-6723. (Pubitemid 19236335)
12. Natali PG, Viora M, Nicotra MR, Giacomini P, Bigotti A, Ferrone S. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst 1983; 71: 439-447. (Pubitemid 13012117)
13. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44: 3930-3935. (Pubitemid 14041618)
14. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994; 153: 1225-1237. (Pubitemid 24228514)
15. Gasparollo A, Coral S, Ciullo M, Prisco A, Cattarossi I, Sigalotti L et al. Unbalanced expression of HLA-A and-B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma. Int J Cancer 2001; 91: 500-507. (Pubitemid 32115105)
16. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995; 55: 3149-3157.
17. Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65: 3937-3941. (Pubitemid 40616376)
18. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 745-754. (Pubitemid 29122593)
19. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48: 1019-1025. (Pubitemid 18061905)
20. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87: 284-292.
21. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in b2-microglobulin messenger RNA. J Clin Invest 1993; 91: 684-692. (Pubitemid 23064155)
22. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
23. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. b2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101: 2720-2729. (Pubitemid 28294581)
24. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hotspot b2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigenprocessing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005; 174: 1462-1471.
25. Hellstrom I, Hellstrom KE, Pierce GE, Yang JP. Cellular and humoral immunity to different types of human neoplasms. Nature 1968; 220: 1352-1354.
26. Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Fairley GH, Bodenham DC et al. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J 1969; 3: 547-552.
27. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29: 550-557.
28. Mahato RI, Rolland A, Tomlinson E. Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharm Res 1997; 14: 853-859. (Pubitemid 27326978)
29. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311. (Pubitemid 23354418)
30. San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781-788. (Pubitemid 24305772)
31. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163: 1552-1561. (Pubitemid 29352779)
32. Yasuda K, Ogawa Y, Kishimoto M, Takagi T, Hashida M, Takakura Y. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motifindependent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun 2002; 293: 344-348. (Pubitemid 34694213)
33. Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2005; 2: 22-28. (Pubitemid 40314726)
34. U'Ren L, Kedl R, Dow S. Vaccination with liposome-DNA complexes elicits enhanced antitumor immunity. Cancer Gene Ther 2006; 13: 1033-1044. (Pubitemid 44564739)
35. Lanuti M, Rudginsky S, Force SD, Lambright ES, Siders WM, Chang MY et al. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000; 60: 2955-2963. (Pubitemid 30395821)
36. Siders WM, Vergillis K, Johnson C, Scheule RK, Kaplan JM. Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination. Mol Ther 2002; 6: 519-527. (Pubitemid 35214874)
37. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352-354. (Pubitemid 26250262)
38. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745. (Pubitemid 32015992)
39. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760. (Pubitemid 34293438)
40. Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and-independent pathways. J Leukoc Biol 2005; 77: 71-79. (Pubitemid 40310695)
41. Fox BA, Drury M, Hu HM, Cao Z, Huntzicker EG, Qie W et al. Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells. Cancer Gene Ther 1998; 5: 307-312. (Pubitemid 128640017)
42. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. b2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Res 1997; 7(Suppl 2): S67-S74. (Pubitemid 27501628)
43. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61: 1095-1099. (Pubitemid 32174430)
44. Leong SP, Muller J, Yetter RA, Gorelik E, Takami T, Hearing VJ. Expression and modulation of a retrovirus-associated antigen by murine melanoma cells. Cancer Res 1988; 48: 4954-4958.
45. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
46. Lesslauer W, Koning F, Ottenhoff T, Giphart M, Goulmy E, van Rood JJ. T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation. Eur J Immunol 1986; 16: 1289-1296. (Pubitemid 17171536)
47. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87: 5031-5035.
48. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79. (Pubitemid 23345240)
49. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366. (Pubitemid 29374833)
50. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
51. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
52. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
53. Di Rosa F, Santoni A. Memory T-cell competition for bone marrow seeding. Immunology 2003; 108: 296-304. (Pubitemid 36332387)
54. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005; 174: 7654-7664. (Pubitemid 40806270)
55. Massberg S, Schaerli P, Knezevic-Maramica I, Kollnberger M, Tubo N, Moseman EA et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007; 131: 994-1008. (Pubitemid 350138089)
56. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388-15393. (Pubitemid 27009610)
57. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4: 419-425. (Pubitemid 27226584)
58. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15: 341-349. (Pubitemid 27020592)